|
1
|
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection.
|
J Clin Psychiatry
|
2012
|
1.42
|
|
2
|
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
|
Int Clin Psychopharmacol
|
2009
|
0.85
|
|
3
|
Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
|
CNS Drugs
|
2012
|
0.85
|
|
4
|
Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
|
Eur Neuropsychopharmacol
|
2011
|
0.84
|
|
5
|
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
|
Int J Neuropsychopharmacol
|
2012
|
0.84
|
|
6
|
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
|
J Clin Psychopharmacol
|
2013
|
0.78
|
|
7
|
THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.
|
Orphanet J Rare Dis
|
2014
|
0.77
|
|
8
|
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
|
Schizophr Res
|
2009
|
0.76
|
|
9
|
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
|
J Clin Psychiatry
|
2012
|
0.75
|
|
10
|
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
|
J Clin Psychopharmacol
|
2013
|
0.75
|
|
11
|
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).
|
Pharmacoepidemiol Drug Saf
|
2011
|
0.75
|
|
12
|
Ziprasidone and the relative risk of diabetes.
|
Br J Psychiatry
|
2011
|
0.75
|
|
13
|
Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.
|
J Affect Disord
|
2012
|
0.75
|